Recursion Pharmaceuticals Inc (RXRX)
7.94
+0.24
(+3.12%)
USD |
NASDAQ |
Apr 24, 16:00
8.07
+0.13
(+1.64%)
After-Hours: 04:50
Recursion Pharmaceuticals Total Liabilities (Quarterly): 190.26M for Dec. 31, 2023
Total Liabilities (Quarterly) Chart
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 190.26M |
| September 30, 2023 | 192.86M |
| June 30, 2023 | 197.74M |
| March 31, 2023 | 197.19M |
| December 31, 2022 | 215.48M |
| September 30, 2022 | 223.50M |
| June 30, 2022 | 234.94M |
| Date | Value |
|---|---|
| March 31, 2022 | 240.75M |
| December 31, 2021 | 67.41M |
| September 30, 2021 | 59.57M |
| June 30, 2021 | 55.88M |
| March 31, 2021 | 504.97M |
| December 31, 2020 | 504.87M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
55.88M
Minimum
Jun 2021
504.97M
Maximum
Mar 2021
221.96M
Average
197.74M
Median
Jun 2023
Total Liabilities (Quarterly) Benchmarks
| Eli Lilly and Co | 53.14B |
| Palatin Technologies Inc | 24.94M |
| Oragenics Inc | 1.798M |
| Editas Medicine Inc | 150.06M |
| BioXcel Therapeutics Inc | 130.21M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 653.70M |
| Shareholders Equity (Quarterly) | 463.44M |
| Debt to Equity Ratio | 0.0025 |
| Current Ratio | 4.702 |
| Net Debt Paydown Yield | -0.00% |